🇺🇸 FDA
Pipeline program

Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients with Advanced Solid Tumors

Phase 2 other active

Quick answer

Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients with Advanced Solid Tumors for advanced solid tumors is a Phase 2 program (other) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
advanced solid tumors
Phase
Phase 2
Modality
other
Status
active

Clinical trials